252 related articles for article (PubMed ID: 37041663)
1. A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.
Lee MMY; Sattar N
Diabetes Obes Metab; 2023 Jul; 25 Suppl 3():33-47. PubMed ID: 37041663
[TBL] [Abstract][Full Text] [Related]
2. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
3. What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.
Sevre K; Rist A; Wachtell K; Devereux RB; Aurigemma GP; Smiseth OA; Kjeldsen SE; Julius S; Pitt B; Burnier M; Kreutz R; Oparil S; Mancia G; Zannad F
Am J Hypertens; 2024 Jan; 37(1):1-14. PubMed ID: 37551929
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
Peters AE; DeVore AD
Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
[TBL] [Abstract][Full Text] [Related]
5. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
6. The current best drug treatment for hypertensive heart failure with preserved ejection fraction.
Rist A; Sevre K; Wachtell K; Devereux RB; Aurigemma GP; Smiseth OA; Kjeldsen SE; Julius S; Pitt B; Burnier M; Kreutz R; Oparil S; Mancia G; Zannad F
Eur J Intern Med; 2024 Feb; 120():3-10. PubMed ID: 37865559
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
[TBL] [Abstract][Full Text] [Related]
8. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
9. Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease.
Khan MS; Rashid AM; Shafi T; Ferreira JP; Butler J
Semin Nephrol; 2023 May; 43(3):151429. PubMed ID: 37871362
[TBL] [Abstract][Full Text] [Related]
10. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
Yan BW; Spahillari A; Pandya A
Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
[TBL] [Abstract][Full Text] [Related]
12. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
14. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Berezin AE; Berezin AA
Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
[TBL] [Abstract][Full Text] [Related]
15. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.
Samsky MD; Lin L; Greene SJ; Lippmann SJ; Peterson PN; Heidenreich PA; Laskey WK; Yancy CW; Greiner MA; Hardy NC; Kavati A; Park S; Mentz RJ; Fonarow GC; O'Brien EC
JAMA Cardiol; 2020 Mar; 5(3):292-299. PubMed ID: 31734700
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
17. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
18. Consensus statement on the current pharmacological prevention and management of heart failure.
Sindone AP; De Pasquale C; Amerena J; Burdeniuk C; Chan A; Coats A; Hare DL; Macdonald P; Sverdlov A; Atherton JJ
Med J Aust; 2022 Aug; 217(4):212-217. PubMed ID: 35908234
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
[TBL] [Abstract][Full Text] [Related]
20. Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey.
Fauvel C; Bonnet G; Mullens W; Giraldo CIS; Mežnar AZ; Barasa A; Tokmakova M; Shchendrygina A; Costa FM; Mapelli M; Zemrak F; Tops LF; Jakus N; Sultan A; Bahouth F; Hadjseyd CE; Salvat M; Anselmino M; Messroghli D; Weberndörfer V; Giverts I; Bochaton T; Courand PY; Berthelot E; Legallois D; Beauvais F; Bauer F; Lamblin N; Damy T; Girerd N; Sebbag L; Pezel T; Cohen-Solal A; Rosano G; Roubille F; Mewton N
Eur J Heart Fail; 2023 Feb; 25(2):213-222. PubMed ID: 36404398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
